The Infusion Pump market size was valued at USD 11.79 billion in 2023. The Cell Culture Media Market industry is projected to grow from USD 12.75 billion in 2024 to USD 21.2 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.56% during the forecast period (2024 - 2032).Rising use in hospitals and increased incidences of chronic diseases are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The majority of infusion pumps come equipped with safety precautions and built-in alarms that are programmed to sound in the event of an issue. In order to treat a number of disorders that cannot be managed by taking oral drugs, including immunological deficiencies, cancer, and congestive heart failure, infusion therapy is required. As a result, it is projected that applications such as these will boost the CAGR of the Infusion Pump market.
Intravenous smart pumps are intravenous pumps that have cutting-edge technology features for accurate, precise, and regulated delivery. These cutting-edge technological features include automation, drug libraries, and different operator and patient safety features. Smart pumps are also known as intelligent pumps. When administering chemotherapy, the patient may benefit from receiving an infusion of fluids of this kind. Therefore, growing improvements are the primary driver of revenue growth in the infusion pump market.
After the introduction of the insulin pump by key market companies like as Medtronic and Insulet Corporation, among others, the market is experiencing a considerable uptick in interest. It is anticipated that the market would rise at a significant pace of growth due to the key factors like the growing prevalence of chronic diseases, advancements in drug delivery technologies, and increasing use of these techniques in emerging regions. Additionally, the expanding population of elderly people who require long-term care therapies is what is driving the development of new products targeting home-based infusion therapies. The most important market companies are concentrating their efforts on the management of speciality drugs at the point of care.
July 2023:Becton Dickinson was able to restart distribution of its system after receiving 510(k) clearance from the FDA for its revised Alaris infusion pump. This authorization will allow the business to remediate or replace previous Alaris devices that are currently being utilized on the market in the United States. Three years after the firm issued a worldwide recall of Alaris infusion pumps because of multiple system-, software-, and user-related difficulties, the company is hoping that the FDA clearance for its upgraded Alaris system would allow for "return to full commercial operations." This comes after the company issued the recall three years ago.
November 2023: Terumo Corporation has unveiled plans for a new production unit within its medical care solutions division. It will be situated in Kofu Factory in Yamanashi, Japan.
August 2023: Virginia Oncology Associates (VOA) acquired the Ivenix Infusion System for administering drugs to patients. This was done through a contract with Fresenius Kabi.June 2023: Eitan Medical Company, which specializes in advanced infusion therapy and drug delivery solutions, sold and transferred its wearable injectors business to LTS, a cutting-edge pharmaceutical technology company that develops and manufactures innovative drug delivery systems. Selling the wearable injectors business followed Eitan Medical’s strategic decision to concentrate on its core infusion treatment portfolio.May 2023: Terumo Blood and Cell Technologies partnered with BioCentriq to demonstrate how their automated cell and gene therapy platforms can expedite CAR-T cell development.February 2023: The newly released BeneFusion i Series and u Series infusion systems by Mindray boast high precision, adaptive customization, and medication safety in various clinical settings, among other features. The latest generation of smart pumps can be employed in obstetrics, endoscopy cancer rooms, including emergency departments, as they now have better elements characterized by increased affordability as well as patient safety enhancement, reducing medication mistakes while improving staff work processes, thus leading to productivity advancements across departments.For instance, Medtronic plc launched one of the first infusion sets labeled for up to seven-day wear in the United States in November 2022. By using special materials that help decrease insulin preservative loss and maintain insulin flow and stability, hence extending the life of an infusion set twice before the Medtronic Extended infusion set does thisAugust 2022: Baxter International Inc., a leader in innovative technology for medication delivery, received the United States Food and Drug Administration (FDA) clearance under section 510(k) for Novum IQ syringe infusion pump (SYR) with Dose IQ Safety Software, Baxter’s latest infusion therapy advances.March 2022: Shanghai MicroPort Lifesciences Co., Ltd. (MicroPort Lifesciences) has obtained marketing approval from China's National Medical Products Administration for its new AutoEx Chemotherapy Infusion Pump (AutoEx).
The ability to deliver fluids in extremely small volumes is just one of the benefits infusion pumps have over the manual administration of medicated fluids. Additionally, it offers the capacity to deliver fluids at precisely predetermined rates or automatically spaced intervals. As a result, healthcare systems continue to adopt them widely. However, the primary growth inhibitors for the market are product recalls and infusion pump issues, such as software flaws and user interface problems.
The rapid growth of the elderly population, the rise in the incidence of chronic diseases, the rising demand for ambulatory infusion pumps, and the rising number of surgical procedures are the main factors propelling the market's expansion. Intensive fluids, including high-risk medications, are administered using intravenous infusion pumps. Most infusion pumps come with security features and built-in alarms meant to activate in case of a problem. Infusion therapy is necessary to treat several conditions without oral medications, including immune deficiencies, cancer, and congestive heart failure. Therefore, such applications are anticipated to enhance the Infusion Pump market CAGR.
Moreover, Another advantage of intravenous infusion pumps is the ability to add vitamins, minerals, amino acids, and various essential micronutrients to the infusion while administering medication to provide collateral nutrition. Smart pumps are intravenous pumps with cutting-edge technological features for accurate, precise, and controlled delivery, including automation, drug libraries, and various operator and patient safety features. Such fluid infusion into the patient's body is helpful when treating chemotherapy. Hence, growing advancements drive the Infusion Pump market revenue growth.
Based on fusion type, the market segments of Infusion Pump includes Volumetric Pumps and Syringe pumps. The Volumetric Pumps segment held the majority share in 2020, contributing around ~65-67% of the Infusion Pump market revenue. Most volumetric pumps operate using one of two common mechanisms: a rotary or reciprocating mechanism. Positive displacement pumps are used by engineers in pressurized fluid systems, particularly in the chemical industry. Volumetric pumps can deliver fluids continuously in very precise amounts at very slow to fast rates. Syringe Pump is anticipated to grow with the fastest CAGR during the forecast period. New product launches and growing R&D activities are expected to fuel the market growth during the forecast period.
January 2018:Chennai-based healthcare startup vTitan launched Syringe infusion pumps—a next-generation medical device. They are used for accurate and secure medication infusions during acute care administration in healthcare facilities and at home. The company has unveiled the Accuflow SP-550 and Accuflow IBP-550 Syringe Infusion Pumps, powered by locally created and patented closed-loop motion control technology.
Figure 2: Infusion Pump Market, by Type, 2024 & 2032 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on application, the Infusion Pump market segmentation includes chemotherapy, diabetes, gastrointestinal diseases, and pediatrics. The pediatrics segment dominated the market in 2020 and is projected to be the faster-growing segment during the forecast period, 2020-2027. The demand for high-quality pediatric care has increased along with the significant advancements in pediatric medicine and the rising birth rate. This segment uses intravenous infusion pumps primarily for their medical procedures, which call for delivering fluids at a specific and programmed rate that can be adjusted. Hence, the growing application of Infusion pumps among the pediatric population is positively impacting the market growth.
Based on End Users, the Infusion Pump industry has been segmented into Hospitals, Ambulatory Surgical Centers, and Homecare. Hospitals held the largest segment share in 2020. The market is expected to grow due to hospitals' strong purchasing power for expensive infusion devices, their large patient base, and their access to skilled professionals who can operate infusion pumps. Home healthcare is anticipated to grow at the highest CAGR during the forecast period. Worldwide government initiatives to reduce healthcare costs associated with longer hospital stays support the growing demand for infusion systems in the home healthcare segment.
April 2023:Fresenius Kabi made the announcement that the Ivenix infusion system received a contract for Innovative Technology by Vizient. The Innovative Technology contracts are recommended following a review and engagement with items that were submitted through the organization's program. Vizient members include more than half of all acute care hospitals in the United States. The contract lays out the parameters for how medical facilities can evaluate and buy the Ivenix system. We are quite proud of the fact that the Ivenix Infusion System was found to have the potential to promote clinical efficiency as well as improve patient outcomes when it was evaluated as part of the Vizient Innovative Technology process, which is a rigorous, clinician-led evaluation.
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific Infusion Pump Market accounted for USD 1.8 billion in 2020 and is expected to exhibit a significant CAGR growth during the study period. Asian nations have dense populations and a high prevalence of chronic diseases like cancer, diabetes, and cardiovascular diseases. These nations are favored destinations for medical tourism because of their reputation for affordable healthcare and surgical procedures. Asian emerging economies with sophisticated healthcare infrastructure and facilities include China, Japan, and India. Moreover, China Infusion Pump held the largest market share, and the India market of Infusion Pump was the fastest growing market in the Asia-Pacific region.
The North America Infusion Pumps market held the second largest market in 2020. The rising prevalence of chronic diseases aided the development of the intravenous pump industry in this area, rising surgical procedures, well-developed and expanding R&D, and rising adoption of cutting-edge infusion pump technology.
Further, the major countries studied in the market report are: The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: INFUSION PUMP MARKET SHARE BY REGION 2020 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Infusion Pump market accounts for the third-largest market share in 2020. Infusion systems can now communicate with the electronic medical record using interoperability software thanks to advancements in infusion technology. The ability to communicate and exchange data with various information technology systems, software applications, and networks in various settings is made possible by interoperability software. This development will increase infusion pump usage and demand in the coming years, driving the market for infusion pumps forward. Further, the Germany market of Infusion Pump held the largest market share, and the market of Infusion Pump was the fastest growing market in the European region.
Infusion Pump Key Market Players & Competitive Insights
Major market players are investing in R&D to expand their product lines, which will fuel the growth of the infusion pump industry. Participants in the market are also undertaking various strategic initiatives to expand their footprint. Significant market developments include new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other players.
Introducing new products is one of the primary business strategies manufacturers adopt in the Infusion Pump industry. The Infusion Pumps industry has recently been adopted in many hospitals and home care. The Infusion Pumps markets major players such as 3M, BRAUN MELSUNGEN AG, Baxter, Becton Dickinson and Company, Fresenius Kabi AG, ICU Medical Inc, Smiths Medical, and Terumo Medical Corporation, and others are working on expanding the market demand by investing in research and development activities.
Baxter is based in Deerfield, Illinois. The company's main focus areas are kidney disease treatments and other chronic and urgent medical conditions. In August 2020, Baxter International Inc. announced The FDA 510(k) clearance of Baxter's new Novum IQ syringe infusion pump (SYR) with Dose IQ Safety Software, one of the company's most recent innovations for infusion therapy. The IQ Enterprise Connectivity Suite from Baxter enables the Novum IQ SYR to integrate seamlessly with hospital electronic medical records (EMRs).
Becton, Dickinson, and Company, or BD, produces and markets reagents, instrument systems, and medical devices. In some regions, BD also offers consulting and analytics services. In April 2021, Becton Dickinson submitted a new 510(k) for its Alaris infusion pump system, which has been the subject of numerous software and hardware recalls over the previous year. The submission aims to "update the regulatory clearance for the BD Alaris System, implement new features, and address open recall issues, including through a new version of BD Alaris System software."
Key Companies in the Infusion Pump market include
April 2021:The Medtronic Extended infusion set, the first and only infusion set that can be worn for up to 7 days, was launched in a few European countries by Medtronic plc. An infusion set, tubes that transport insulin from the pump to the body, typically needs to be changed every few days.
February 2021:A ground-breaking, effective infusion system for the healthcare sector, the BeneFusion e Series from Mindray, was unveiled. The BeneFusion e Series, which comes in three models named eSP, eVP, and eDS, offers workflow, safety, application, and informatics efficiency. In a few countries and regions, this new series will be accessible.
Volumetric Pump
Syringe Pump
Chemotherapy
Diabetes
Gastrointestinal Diseases
Pediatrics
Hospitals
Ambulatory Surgical Centers
Homecare
Infusion Pump Regional Outlook
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)